AVBP Stock Price, Chart, Stats & News
ArriVent BioPharma, Inc. Common Stock (AVBP) does not currently pay a dividend.
AVBP chart
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -49.92% |
ROE | -62.48% |
D/E | 0.00x |
Interest coverage ratio | – |
AVBP valuation
P/E | – |
P/S | – |
P/B | 2.68x |
P/CF | -5.13x |
P/FCF | -5.90x |
P/OCF | -5.13x |
PEG | 0.91x |
EV multiple | -5.77x |
About
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company’s lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002, ARR-421, and ARR-173 for solid tumors.
Similar securities
Based on sector and market capitalization
